| NAME |
TAZEMETOSTAT 200MG TAB |
| VA GENERIC NAME |
TAZEMETOSTAT |
| DOSAGE FORM |
TAB |
| FDA MED GUIDE |
Tazemetostat_(Tazverik)_(Jun_2020).pdf |
| HAZARDOUS TO DISPOSE |
NO |
| FORMULARY DESIGNATOR |
PA-F |
| FORMULARY DESIGNATOR TEXT |
Tazemetostat is a methyltransferase inhibitor with approval for epithelioid sarcoma and relapsed/refractory follicular lymphoma
|
| ACTIVE INGREDIENTS |
|
| NATIONAL FORMULARY INDICATOR |
YES |
| CS FEDERAL SCHEDULE |
Unscheduled |
| STRENGTH |
200 |
| SINGLE/MULTI SOURCE PRODUCT |
Multisource |
| UNITS |
MG |
| NATIONAL FORMULARY NAME |
TAZEMETOSTAT TAB |
| CREATE DEFAULT POSSIBLE DOSAGE |
YES |
| CODING SYSTEM |
|
| COPAY TIER |
-
- COPAY TIER LEVEL: 3
- COPAY EFFECTIVE DATE: 2020-02-06 00:00:00
|
| PGX ELIGIBLE |
NO |
| PGX SUPPRESSED |
NO |
| VA PRINT NAME |
TAZEMETOSTAT 200MG TAB |
| VA PRODUCT IDENTIFIER |
T1052 |
| TRANSMIT TO CMOP |
NO |
| VA DISPENSE UNIT |
TAB |
| MASTER ENTRY FOR VUID |
YES |
| VUID |
4039126 |
| EFFECTIVE DATE/TIME |
-
- 2020-02-06 00:00:00
- STATUS: ACTIVE
|
